ProLynx Inc.
PrivateLast Round
Series A
Dec 11, 2025
Total Funding Raised
$72.65M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ProLynx Inc. is a biotechnology company developing a portfolio of ultra-long-acting medicines for obesity and related metabolic diseases using its proprietary half-life extension technology platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ProLynx Inc. Comparables
Compare ProLynx Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Serina Therapeutics Inc | 79% | |
| InnoCore Pharmaceuticals | 79% | |
| Johnson & Johnson | 76% |
ProLynx Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 11, 2025 | ||||
| Seed | Sep 10, 2020 | ||||
| Grant | Jul 7, 2020 | ||||
| Debt | Apr 14, 2020 | ||||
| Grant | Nov 1, 2018 | ||||
Grant | Sep 25, 2017 |
ProLynx Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| OrbiMed | Series A |
| 5AM Ventures | Series A |
| Monograph Capital | Series A |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 46% MoM.
- Jul 29, 2026
Grew 15% QoQ, from 33 to 38 employees.
Recent news
Latest coverage and updates
- hiresJul 15, 2026
Prolynx LLC hired Simon Harnest as Chief Financial Officer on Jul 15th '26.
- hiresJul 15, 2026
Prolynx LLC hired Amer Mirza as Chief Scientific Officer on Jul 16th '26.
ProLynx Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ProLynx Inc.'s valuation, stock price, and market status.
Is ProLynx Inc. a public or private company?
ProLynx Inc. is a private company.
What is the current stock price of ProLynx Inc.?
ProLynx Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is ProLynx Inc. worth (valuation)?
Valuation information for ProLynx Inc. is not publicly available.
Can I buy ProLynx Inc. stock?
ProLynx Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ProLynx Inc.'s last funding round?
ProLynx Inc.'s most recent funding round was Series A on December 11, 2025.
Who are the main investors in ProLynx Inc.?
Key investors in ProLynx Inc. include NIH RADx, OrbiMed, 5AM Ventures, Monograph Capital, National Science Foundation.
Will ProLynx Inc. IPO soon?
No public IPO plans have been announced for ProLynx Inc..
How can I track ProLynx Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ProLynx Inc.'s secondary market activity and sign up for updates.